Onsdag den 13 mars välkomnades GOKAP Invests stora delägarskara och entreprenörer till ett portföljmöte i Mariasalen vid GU Ventures lokaler i centrala Göteborg. Evenemanget blev välbesökt med drygt 90 investerare på plats.
Read More
Sortina Pharma, an oncology focused startup founded in 2020 based on research originating from Gothenburg University, today announces the official publication of the issued Swedish patent no. 2151469-0, which relates to novel sortilin binding molecules inhibiting the binding of effector molecules to sortilin.
Read More
Sara has a doctoral degree in immunology from Gothenburg University and has been managing and driving the sortilin-project from research into product development. She has extensive experience in cancer research and has been one of the lead scientists for the sortilin-project initiated at the University of Gothenburg. She has co-founded Sortina Pharma together with professor Göran Landberg and GU Ventures in 2020.
Read More
Sortina Pharma AB today announces a financing led by the venture capital fund Eir Ventures and with GU Ventures, to unlock the potential of proprietary anti-sortilin cancer therapy to cure aggressive cancer.
Read More
With the agreement that has now been concluded between Iscaffpharma and Sortina Pharma, more effective products to cure aggressive breast cancer can be generated. Sortina Pharma, which is developing a new medical treatment, can now benefit from Iscaffpharma's unique technology. This provides a drug fingerprint predicting the effects in humans for new cancer drugs.
Read More